Back to Search Start Over

NEDD4L intramolecular interactions regulate its auto and substrate Na V 1.5 ubiquitination.

Authors :
Wright KM
Nathan S
Jiang H
Xia W
Kim H
Chakouri N
Nwafor JN
Fossier L
Srinivasan L
Chen Z
Boronina T
Post J
Paul S
Cole RN
Ben-Johny M
Cole PA
Gabelli SB
Source :
The Journal of biological chemistry [J Biol Chem] 2024 Mar; Vol. 300 (3), pp. 105715. Date of Electronic Publication: 2024 Feb 02.
Publication Year :
2024

Abstract

NEDD4L is a HECT-type E3 ligase that catalyzes the addition of ubiquitin to intracellular substrates such as the cardiac voltage-gated sodium channel, Na <subscript>V</subscript> 1.5. The intramolecular interactions of NEDD4L regulate its enzymatic activity which is essential for proteostasis. For Na <subscript>V</subscript> 1.5, this process is critical as alterations in Na <superscript>+</superscript> current is involved in cardiac diseases including arrhythmias and heart failure. In this study, we perform extensive biochemical and functional analyses that implicate the C2 domain and the first WW-linker (1,2-linker) in the autoregulatory mechanism of NEDD4L. Through in vitro and electrophysiological experiments, the NEDD4L 1,2-linker was determined to be important in substrate ubiquitination of Na <subscript>V</subscript> 1.5. We establish the preferred sites of ubiquitination of NEDD4L to be in the second WW-linker (2,3-linker). Interestingly, NEDD4L ubiquitinates the cytoplasmic linker between the first and second transmembrane domains of the channel (DI-DII) of Na <subscript>V</subscript> 1.5. Moreover, we design a genetically encoded modulator of Nav1.5 that achieves Na <superscript>+</superscript> current reduction using the NEDD4L HECT domain as cargo of a Na <subscript>V</subscript> 1.5-binding nanobody. These investigations elucidate the mechanisms regulating the NEDD4 family and furnish a new molecular framework for understanding Na <subscript>V</subscript> 1.5 ubiquitination.<br />Competing Interests: Conflict of interest The authors declare no conflicts of interest in regards to this manuscript. S. B. G. is a cofounder and equity holder in the company Advanced Molecular Sciences, LLC. S. B. G. has been or is a consultant for Scorpion Therapeutics and Xinthera. P. A. C. has been a consultant for Scorpion Therapeutics.<br /> (Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)

Details

Language :
English
ISSN :
1083-351X
Volume :
300
Issue :
3
Database :
MEDLINE
Journal :
The Journal of biological chemistry
Publication Type :
Academic Journal
Accession number :
38309503
Full Text :
https://doi.org/10.1016/j.jbc.2024.105715